Get the Stockscreener App
6.92
8.98%
0.57
Pre-market:
6.88
-0.04
-0.58%
Immuneering Corp stock is traded at $6.92, with a volume of 1.07M.
It is up +8.98% in the last 24 hours and up +24.01% over the past month.
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
See More
Previous Close:
$6.35
Open:
$6.39
24h Volume:
1.07M
Relative Volume:
0.58
Market Cap:
$410.02M
Revenue:
$317.00K
Net Income/Loss:
$-53.47M
P/E Ratio:
-3.6614
EPS:
-1.89
Net Cash Flow:
$-49.31M
1W Performance:
+0.14%
1M Performance:
+24.01%
6M Performance:
+380.56%
1Y Performance:
+284.44%
1-Day Range:
$6.2809
$7.045
1-Week Range:
$6.0002
$7.57
52-Week Range:
$1.10
$10.08
Immuneering Corp Stock (IMRX) Company Profile
Name
Immuneering Corp
Sector
Industry
Phone
617-500-8080
Address
245 MAIN STREET, SECOND FLOOR, CAMBRIDGE
Compare IMRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMRX
Immuneering Corp
|
6.92 | 410.02M | 317.00K | -53.47M | -49.31M | -1.89 |
|
ARGX
Argen X Se Adr
|
929.61 | 55.90B | 3.06B | 1.28B | 447.35M | 19.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
434.02 | 110.91B | 11.74B | 3.68B | 3.34B | 14.19 |
|
INSM
Insmed Inc
|
197.40 | 41.21B | 447.02M | -1.18B | -906.14M | -6.1812 |
|
ONC
Beone Medicines Ltd Adr
|
376.63 | 40.48B | 4.98B | 69.59M | 525.67M | 0.5197 |
|
REGN
Regeneron Pharmaceuticals Inc
|
704.31 | 72.89B | 14.25B | 4.58B | 3.88B | 41.77 |
Immuneering Corp Stock (IMRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-31-25 | Initiated | Leerink Partners | Outperform |
| Dec-13-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Mar-15-24 | Downgrade | Jefferies | Buy → Hold |
| Mar-15-24 | Reiterated | Needham | Buy |
| Mar-15-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Dec-01-23 | Initiated | Needham | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Apr-19-23 | Upgrade | Mizuho | Neutral → Buy |
| Apr-19-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Mar-30-23 | Initiated | Mizuho | Neutral |
| Feb-03-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-08-22 | Initiated | Chardan Capital Markets | Buy |
| Apr-01-22 | Initiated | Oppenheimer | Outperform |
| Jan-07-22 | Initiated | Piper Sandler | Overweight |
View All
Immuneering Corp Stock (IMRX) Latest News
How Immuneering Corporation stock compares to growth peersMarket Performance Report & Free Safe Entry Trade Signal Reports - newser.com
Combining machine learning predictions for Immuneering CorporationEntry Point & Free AI Powered Buy and Sell Recommendations - newser.com
Is Immuneering Corporation stock undervalued vs historical averages2025 Valuation Update & Real-Time Stock Movement Alerts - newser.com
Can Immuneering Corporation stock reach $100 price targetGlobal Markets & Risk Adjusted Swing Trade Ideas - newser.com
Is Immuneering Corporation stock poised for growthAnalyst Downgrade & Daily Volume Surge Signals - newser.com
What data driven models say about Immuneering Corporation’s futureMarket Activity Summary & Safe Entry Point Alerts - newser.com
Why Immuneering Corporation stock is recommended by analystsWeekly Market Outlook & Fast Exit and Entry Trade Guides - newser.com
Can momentum traders help lift Immuneering CorporationJuly 2025 Analyst Calls & Advanced Technical Analysis Signals - newser.com
Does Immuneering Corporation qualify in momentum factor screeningEarnings Overview Summary & Risk Managed Trade Strategies - newser.com
Immuneering Corporation (NASDAQ:IMRX) Q3 2025 Earnings Call Transcript - Insider Monkey
Immuneering Corp. Shines in Positive Earnings Call - TipRanks
What momentum indicators show for Immuneering Corporation stockWeekly Stock Report & High Return Trade Guides - newser.com
Immuneering rises after smaller-than-expected Q3 loss - TradingView
Immuneering Corp. Reports Strong Q3 2025 Progress - TipRanks
Earnings call transcript: Immuneering Q3 2025 emphasizes cash boost and trial progress - Investing.com Nigeria
Immuneering Corporation (IMRX) Q3 FY2025 earnings call transcript - Yahoo Finance
Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates - The Manila Times
Immuneering Corporation Reports 86% Overall Survival in Pancreatic Cancer Patients and Secures $225 Million in Financing - Quiver Quantitative
What indicators show strength in Immuneering CorporationWeekly Gains Report & Stepwise Entry/Exit Trade Alerts - newser.com
A look into Immuneering Corp (IMRX)’s deeper side - setenews.com
A Preview Of Immuneering's Earnings - Benzinga
Trend analysis for Immuneering Corporation this weekWeekly Market Report & Low Drawdown Momentum Ideas - newser.com
Are These 4 Biotech Stocks Set to Beat Q3 Earnings Estimates? - Yahoo Finance
Immuneering (IMRX) to Release Earnings on Wednesday - Defense World
How to read the order book for Immuneering CorporationJuly 2025 Chart Watch & Risk Adjusted Buy and Sell Alerts - newser.com
Will Immuneering Corporation stock attract more institutional investors2025 Year in Review & High Accuracy Swing Entry Alerts - Fundação Cultural do Pará
Immuneering Corp Stock (IMRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.99%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):